Reslizumab
C38072/3085
Phase 3 small_molecule terminated
Quick answer
Reslizumab for Eosinophilic Asthma is a Phase 3 program (small_molecule) at Teva Generics B.V with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Generics B.V
- Indication
- Eosinophilic Asthma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated